477 related articles for article (PubMed ID: 17275476)
1. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
[TBL] [Abstract][Full Text] [Related]
2. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
[TBL] [Abstract][Full Text] [Related]
3. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
Schulz T; Papapostolou G; Schenker P; Kapischke M
Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
[TBL] [Abstract][Full Text] [Related]
4. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
6. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
7. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
Schulz T; Flecken M; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
[TBL] [Abstract][Full Text] [Related]
8. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
[TBL] [Abstract][Full Text] [Related]
9. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
Schnetzler B; Leger P; Völp A; Dorent R; Pavie A; Gandjbakhch I
Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
[TBL] [Abstract][Full Text] [Related]
11. [Low-dose antithymocyte globulins in kidney transplantation: results of a protocol of intermittent administration].
Mourad G; Portales P; Garrigue V; Djamali A; Bouloux C; Chong G; Clot J
Nephrologie; 2000; 21(5):253-8. PubMed ID: 11068775
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of IgG subclass levels for infectious complications in renal transplant recipients.
Wieneke H; Otte B; Lang D; Heidenreich S
Clin Nephrol; 1996 Jan; 45(1):22-8. PubMed ID: 8616953
[TBL] [Abstract][Full Text] [Related]
13. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
14. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
Schulz T; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
17. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
Giral M; Taddei C; Nguyen JM; Dantal J; Hourmant M; Cantarovich D; Blancho G; Ancelet D; Soulillou JP
Clin Transpl; 1996; ():257-64. PubMed ID: 9286575
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
19. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
[TBL] [Abstract][Full Text] [Related]
20. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
Esposito L; Kamar N; Durand D; Rostaing L
Transplant Proc; 2005 Mar; 37(2):892-4. PubMed ID: 15848567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
